Mylan

Venatorx Pharmaceuticals Expands Senior Leadership Team

Retrieved on: 
Tuesday, March 12, 2024
Research, Infectious Diseases, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Financial management, Quality control, Medication, Virginia University, Information technology, Goldman Sachs, CFO, Business, Shire (pharmaceutical company), State university system, Patient, Accounting, Strategic planning, NDA, CMC, IPO, Senior, HBV, MBA, Ernst & Young, Mylan, Chemistry, Investment, Therapy, Lehigh University, West Virginia University, CPA, Management

"These additions to our senior leadership team are critical to ensure we are prepared for our NDA resubmission and are strategically positioned for continued success."

Key Points: 
  • "These additions to our senior leadership team are critical to ensure we are prepared for our NDA resubmission and are strategically positioned for continued success."
  • He joined Venatorx from Aimmune/Nestle Health Science where he was a Senior Vice President and Head of Technical Operations.
  • Before this, he was the Senior Vice President of Technical Operations with Paratek Pharmaceuticals and over the years has worked at Eagle Pharmaceuticals, Shire with aaiPharma, Elan Pharmaceuticals, Sandoz, and Mylan Pharmaceuticals.
  • Previously, he was Vice President, Technical Assessment and Senior Director for Business Development at Shire Pharmaceuticals to build the product pipeline and support Shire's strategic venture arm through investments.

Proton Capital Enters Into Agreement to Purchase PharmaChoice Canada Branded Pharmacy In Saskatoon For Proposed Qualifying Transaction

Retrieved on: 
Thursday, February 22, 2024
Earnout, Issuer, News, Growth, Edinburgh Business School, Saint, Acquisition, Commerce, Sale, St. Francis Xavier University, Indian stock exchange, University, CPC, PharmaChoice, Offering, Target, Physics, Toronto Stock Exchange, Medication, Pharmacist, Outline of health sciences, Qualification, CMA, McKesson Corporation, Partnership, CPA, Mylan, McDonald House, Transaction, Employment, United, Chair, Federated, Cannabis, Prospectus, BBA, Honor, Marketing, Bookrunner, Food, Bachelor, Audit committee, Executive, SaskTel, All Saints, Security (finance)

The Share Purchase Agreement provides that Proton will purchase 75% of the issued and outstanding shares of the Target Pharmacy.

Key Points: 
  • The Share Purchase Agreement provides that Proton will purchase 75% of the issued and outstanding shares of the Target Pharmacy.
  • The Qualifying Transaction will not constitute a Non-Arm’s Length Qualifying Transaction (as such term is ‎defined in the policies of the TSXV).
  • The parties to the Qualifying Transaction are at arm’s length and therefore the approval of the shareholders of ‎Proton in respect of the Qualifying Transaction will not be required.
  • The Prospectus will contain important detailed information about the Corporation, the Qualifying ‎Transaction and the proposed Offering.

Deb Autor, Former FDA Deputy Commissioner, Appointed CEO of Healthcare Innovation Catalysts

Retrieved on: 
Thursday, February 1, 2024
Research, General Health, Professional Services, Pharmaceutical, Medical Devices, Health Technology, Data Analytics, Science, Biotechnology, Practice Management, Consulting, Health, Partnership, Multimedia, Policy, ABC, CNN, NBC, Knowledge, Government, Mylan, USA Today, FDA, Justice, Amneal Pharmaceuticals, AstraZeneca, Food, The New York Times, CBS, Congress, The Wall Street Journal, Los Angeles Times, Medicine, HIC, Organization

Her government career spanned two decades, culminating in the crucial role of Deputy Commissioner of FDA where she oversaw all inspections and international operations.

Key Points: 
  • Her government career spanned two decades, culminating in the crucial role of Deputy Commissioner of FDA where she oversaw all inspections and international operations.
  • Before FDA, Ms. Autor was a decorated federal prosecutor at the U.S. Department of Justice, and FDA was her client.
  • “We are honored to have Deb take the helm as our first CEO,” stated Michael Singer, Executive Chairman of HIC.
  • Since 2018, she has served as Chair of the FDA Alumni Association, where she continues to work to support the agency’s mission.

iCapital® Names New Marketing Leadership to Drive Global Growth

Retrieved on: 
Tuesday, January 30, 2024
Technology, Finance, Fintech, Banking, Professional Services, Software, Data Analytics, Asset Management, Data Management, Growth, Senior, Marketing, Communication, Ein Sof, Mylan, Advertising, Bankers Trust

"We are delighted to welcome Magdalena and Christine to lead our marketing and communications organization at iCapital" said Lawrence Calcano, Chairman and CEO of iCapital.

Key Points: 
  • "We are delighted to welcome Magdalena and Christine to lead our marketing and communications organization at iCapital" said Lawrence Calcano, Chairman and CEO of iCapital.
  • "As we build the industry operating system for investment excellence in private markets, they will have an important role in iCapital's continuing growth and global expansion."
  • As Chief Marketing Officer, Pandiloska will oversee worldwide marketing and communications, including branding, advertising, content, digital strategy, events, market intelligence, and marketing operations.
  • With more than two decades of global marketing leadership, she joins iCapital from Microsoft Canada where she served as the Chief Marketing Officer responsible for the modern marketing transformation that propelled the brand to the top commercial spot in Canada.

Human medicines European public assessment report (EPAR): Emtricitabine/Tenofovir disoproxil Mylan, emtricitabine,tenofovir disoproxil, Date of authorisation: 16/12/2016, Revision: 15, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Medical Subject Headings, Condom, Marketing, HIV-1, Tenofovir disoproxil, INN, Risk, Immune system, Health care, HIV/AIDS, Infection, Mylan, ATC, AIDS, International, Emtricitabine, Blood, Language, European Medicines Agency, Food, HIV, Tablet, Select, Subtypes of HIV, Patient, Cell, NRTI, Anatomy, Medicine, IIA, Pre-exposure prophylaxis, Generic drug

Human medicines European public assessment report (EPAR): Emtricitabine/Tenofovir disoproxil Mylan, emtricitabine,tenofovir disoproxil, Date of authorisation: 16/12/2016, Revision: 15, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Emtricitabine/Tenofovir disoproxil Mylan, emtricitabine,tenofovir disoproxil, Date of authorisation: 16/12/2016, Revision: 15, Status: Authorised

Nasus Pharma Announces Positive Clinical Results of Recent Phase 2 Study With FMXIN002 Intranasal Epinephrine

Retrieved on: 
Tuesday, December 5, 2023
Epinephrine autoinjector, Safety, Powder, Plasma, Food, PBI, Patient, Journal, Fatality, Pharmacokinetics, Caregiver, Parent, Anaphylaxis, Nasal administration, Trial of the century, Cmax, Death, Emergency, Biting, TEL, Injection, Pharmaceutical industry, Medical device, Mylan, Hadassah, Allergy, Adrenaline

TEL AVIV, Israel, Dec. 5, 2023 /PRNewswire/ -- Nasus Pharma Ltd a clinical-stage biopharmaceutical company focused on developing a needle-free, powder-based Intranasal (PBI) product portfolio to address acute medical conditions announced positive results from its latest clinical study of intranasal powder-based Epinephrine.

Key Points: 
  • TEL AVIV, Israel, Dec. 5, 2023 /PRNewswire/ -- Nasus Pharma Ltd a clinical-stage biopharmaceutical company focused on developing a needle-free, powder-based Intranasal (PBI) product portfolio to address acute medical conditions announced positive results from its latest clinical study of intranasal powder-based Epinephrine.
  • Nasus Pharma recently completed an additional phase 2 study (NP-006-Epinephrine) confirming the superiority and safety of its lead FMXIN002 Intranasal Epinephrine product.
  • The recent clinical study explored the safety and efficacy of FMXIN002 in its intended clinical dose and provided additional compelling evidence to the robustness of Nasus Pharma intranasal powder technology already tested in a  prior pilot study ( Tal, et al.
  • "This phase 2  study indicates that powder-based intranasal epinephrine can offer significant clinical advantages, as compared to the currently-available intramuscular route of drug administration and other solution-based intranasal epinephrine programs in development.

Rajiv Malik to Retire as President of Viatris Effective April 1, 2024

Retrieved on: 
Friday, October 20, 2023
Upjohn, Research, Industrial and Commercial Development Corporation, Mentorship, Trade, Medicine, Development, Pfizer, HIV/AIDS, Retirement, Quality, Information technology, Management, Viatris, Mylan

(NASDAQ: VTRS), a global healthcare company, announced today that its President, Rajiv Malik , will be retiring as an executive of the Company effective April 1, 2024.

Key Points: 
  • (NASDAQ: VTRS), a global healthcare company, announced today that its President, Rajiv Malik , will be retiring as an executive of the Company effective April 1, 2024.
  • Prior to Viatris, Malik served as president of Mylan, which he first joined in 2007 following the Company acquiring a controlling stake in Matrix Laboratories Limited, where he served as chief executive officer from 2005 to 2008.
  • Malik will continue to serve on the Viatris Board of Directors.
  • Robert J. Coury , Executive Chairman of Viatris, said, "There are not enough words to express how much Rajiv Malik as both a partner and a leader has meant to me, first at Mylan and now Viatris.

mRNA/LNP technology platform company etherna names Bernard Sagaert as Chief Executive Officer and Marijn Dekkers as Chairman of the Board

Retrieved on: 
Tuesday, October 17, 2023
Partnership, Dekkers, Traction, RNA, LNP, Therapy, Thermo Fisher Scientific, John Russell Greig, Bayer, Interim, Mylan, Patient, GMP, QA, Messenger, Management, Vaccine

NIEL, Belgium, Oct. 17, 2023 /PRNewswire/ -- etherna ("the Company"), a leading mRNA/LNP technologies company, announced today that Bernard Sagaert has been confirmed-as Chief Executive Officer.

Key Points: 
  • NIEL, Belgium, Oct. 17, 2023 /PRNewswire/ -- etherna ("the Company"), a leading mRNA/LNP technologies company, announced today that Bernard Sagaert has been confirmed-as Chief Executive Officer.
  • At the same time Marijn Dekkers, an existing Board Member representing investor Novalis LifeSciences LLC, has been appointed Chairman of the Board.
  • Marijn Dekkers, new etherna Chairman said: "I am honored to be asked to take the role of Chairman at this exciting Company and working closely with Bernard, the etherna leadership team, and the board.
  • To reflect both the new business strategy, board restructuring and permanent appointment of Sagaert, the Company has also rebranded its name from "eTheRNA Immunotherapies" to "etherna".

Ian Fuller Named Vice President of Operations at Jubilant HollisterStier Contract Manufacturing

Retrieved on: 
Thursday, September 14, 2023
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Manufacturing operations, Dexcom, Jubilant, Multimedia, Real estate, CMO, Mylan, Engineering, Management, Operation

Jubilant HollisterStier Contract Manufacturing is pleased to announce the appointment of Ian Fuller as the new Vice President of Operations.

Key Points: 
  • Jubilant HollisterStier Contract Manufacturing is pleased to announce the appointment of Ian Fuller as the new Vice President of Operations.
  • View the full release here: https://www.businesswire.com/news/home/20230914848840/en/
    Ian Fuller, Vice President of Operations at Jubilant HollisterStier Contract Manufacturing.
  • His recent positions include Senior Director of Global Facilities and Real Estate at Dexcom and Vice President of Manufacturing Operations at Mylan.
  • "I am excited about the challenges and the journey ahead and look forward to contributing to Jubilant HollisterStier's advancement in the CMO industry," commented Mr. Fuller.

Nasus Pharma Announces Publication Of Its Positive Clinical Results With FMXIN002 Intranasal Powder Epinephrine Spray In The Journal Of Allergy And Clinical Immunology In Practice

Retrieved on: 
Tuesday, August 8, 2023
Allergen, Volunteering, PK, Injection, Tmax, Food, Allergy, PBI, Emergency, Biting, Pharmacokinetics, IM, Cmax, Parent, Trial of the century, Nose, Plasma, TEL, Anaphylaxis, AUC, Nasal congestion, Powder, Nasal administration, Death, Fatality, Pharmaceutical industry, Nasus, Adrenaline, Mylan

TEL AVIV, Israel, Aug. 8, 2023 /PRNewswire/ -- Nasus Pharma Ltd a clinical-stage biopharmaceutical company focused on developing needle-free, powder-based Intranasal (PBI) product portfolio, to address acute medical conditions announced the publication of positive results from a clinical study of intranasal powder-based Epinephrine.

Key Points: 
  • FMXIN002 is an investigational intranasal epinephrine powder spray device that is noninvasive, user-friendly and reliable and could provide timely effective rescue for severe potentially life-threatening allergic reactions to food, medications and insect bites.
  • The clinical study provides additional compelling evidence to the robustness of Nasus Pharma's intranasal powder technology already tested in other drugs.
  • "The publication of our results in a prominent scientific journal such as JACI: In Practice will ensure the dissemination of FMXIN002's promise within the relevant medical community."
  • Yet an additional advantage for powder-based formulation of epinephrine, a drug that undergoes rapid degradation in the currently-available short shelf-life liquid dosage forms.